On the relationship between block of the cardiac Na+channel and drug-induced prolongation of the QRS complex

Reducing QT liability and proarrhythmic risk in drug discovery and development

(2010) Jean-Pierre Valentin   BRITISH JOURNAL OF PHARMACOLOGY

Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines

(2010) Jean-Pierre Valentin et al.   BRITISH JOURNAL OF PHARMACOLOGY

An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk

(2010) CE Pollard et al.   BRITISH JOURNAL OF PHARMACOLOGY

An Ion Channel Library for Drug Discovery and Safety Screening on Automated Platforms

(2009) Barbara A. Wible et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance

(2009) B Darpo   BRITISH JOURNAL OF PHARMACOLOGY

Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening

(2009) Jason Cordes et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Is Wider Worse? QRS Duration Predicts Cardiac Mortality in Patients with Right Bundle Branch Block

(2008) Christiana O. Adesanya et al.   ANNALS OF NONINVASIVE ELECTROCARDIOLOGY

Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective

(2008) C E Pollard et al.   BRITISH JOURNAL OF PHARMACOLOGY

High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology

(2008) John Dunlop et al.   NATURE REVIEWS DRUG DISCOVERY

Safety and secondary pharmacology: Successes, threats, challenges and opportunities

(2008) Jean-Pierre Valentin et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks™

(2007) A.R. Harmer et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS